Amoeba SA (ALMIB) - Total Liabilities
Based on the latest financial reports, Amoeba SA (ALMIB) has total liabilities worth €20.64 Million EUR (≈ $24.13 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Amoeba SA (ALMIB) cash conversion ratio to assess how effectively this company generates cash.
Amoeba SA - Total Liabilities Trend (2011–2024)
This chart illustrates how Amoeba SA's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Amoeba SA to evaluate the company's liquid asset resilience ratio.
Amoeba SA Competitors by Total Liabilities
The table below lists competitors of Amoeba SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Future Health Esg Corp
NASDAQ:FHLT
|
USA | $17.44 Million |
|
Shanghai Yaohua Pilkington Glass Group Co Ltd B
SHG:900918
|
China | $3.63 Billion |
|
Northwest Copper Corp
V:NWST
|
Canada | CA$2.55 Million |
|
Ferronordic AB (publ)
ST:FNM
|
Sweden | Skr2.69 Billion |
|
Redtone International Bhd
KLSE:0032
|
Malaysia | RM135.88 Million |
|
Everest Industries Limited
NSE:EVERESTIND
|
India | Rs7.26 Billion |
|
Kukje Pharma Co Ltd
KO:002720
|
Korea | ₩84.80 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Amoeba SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Amoeba SA (ALMIB) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amoeba SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amoeba SA (2011–2024)
The table below shows the annual total liabilities of Amoeba SA from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €16.06 Million ≈ $18.78 Million |
+56.99% |
| 2023-12-31 | €10.23 Million ≈ $11.96 Million |
+141.99% |
| 2022-12-31 | €4.23 Million ≈ $4.94 Million |
-70.44% |
| 2021-12-31 | €14.30 Million ≈ $16.72 Million |
+29.28% |
| 2020-12-31 | €11.06 Million ≈ $12.93 Million |
+15.09% |
| 2019-12-31 | €9.61 Million ≈ $11.24 Million |
+112841.62% |
| 2018-12-31 | €8.51K ≈ $9.95K |
-6.05% |
| 2017-12-31 | €9.06K ≈ $10.59K |
+93.31% |
| 2016-12-31 | €4.69K ≈ $5.48K |
+32.52% |
| 2015-12-31 | €3.54K ≈ $4.13K |
-99.87% |
| 2014-12-31 | €2.75 Million ≈ $3.22 Million |
+52.76% |
| 2013-12-31 | €1.80 Million ≈ $2.11 Million |
+133.74% |
| 2012-12-31 | €770.75K ≈ $901.09K |
+16.57% |
| 2011-12-31 | €661.17K ≈ $772.98K |
-- |
About Amoeba SA
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopath… Read more